NCT06919809 2026-03-09
Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery
McGuire Institute
Phase NA Completed
Clinical Trials
52 trialsNCT07428941 2026-02-24
LegitHealth PH
AI Labs Group S.L
Completed
NCT03889912 2026-01-21
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT04540588 2025-12-02
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
Phase NA Completed
NCT03836105 2025-10-15
CASE
Regeneron Pharmaceuticals
Completed
NCT06880848 2025-09-24
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
Jemincare
Phase 4 Completed
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT04969419 2025-01-14
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
Completed
NCT04470726 2024-12-27
NMSC
AiViva BioPharma, Inc.
Phase 1/2 Completed
NCT06690086 2024-12-09
DERM-SUCCESS
DermaSensor, Inc.
Completed
NCT04893486 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Phase 2 Completed
NCT00472043 2024-08-06
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Galderma R&D
Phase 3 Completed
NCT00472108 2024-08-05
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Galderma R&D
Phase 3 Completed
NCT04925713 2024-08-02
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
TuHURA Biosciences, Inc.
Phase 1 Completed
NCT03703310 2024-07-03
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Completed
NCT03509415 2024-04-16
Reflectance Confocal Microscopy to Diagnose BCC
Skin Care Network Ltd.
Completed
NCT04669808 2024-03-18
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Sirnaomics
Phase 2 Completed
NCT05126173 2023-06-28
DERM US and EU Validation Study
Skin Analytics Limited
Completed
NCT00473343 2023-01-05
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Galderma R&D
Phase 3 Completed
NCT04936932 2022-12-08
Laser Treatment of Basal Cell Carcinoma
Sciton
Phase NA Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT02144077 2022-11-03
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Biofrontera Bioscience GmbH
Phase 3 Completed
NCT00189280 2022-02-22
Aldara for the Treatment of Large and/or Multiple sBCC
Viatris Inc.
Phase 3 Completed
NCT00189241 2022-02-07
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Viatris Inc.
Phase 3 Completed
NCT04279535 2021-11-02
Topical Vitamin C for Treatment of Basal Cell Cancer
Center for Biomedical Research, Inc.
Phase EARLY_PHASE1 Completed
NCT00880308 2020-12-19
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01208831 2020-12-19
An East Asian Study of LDE225
Novartis
Phase 1 Completed
NCT01106508 2020-12-17
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02371967 2020-10-09
ROSETT
Hoffmann-La Roche
Completed
NCT02354261 2020-08-05
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
HedgePath Pharmaceuticals, Inc.
Phase 2 Completed
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT02674009 2019-05-13
NIELS
Hoffmann-La Roche
Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT02438644 2018-02-26
Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina
Hoffmann-La Roche
Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT02409628 2017-09-15
EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds
Neotherix Limited
Phase NA Completed
NCT00968981 2017-07-11
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT00961896 2015-11-03
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Novartis
Phase 2 Completed
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT02097875 2015-04-21
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Blaze Bioscience Australia Pty Ltd
Phase 1 Completed
NCT00108121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Peplin
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT00670189 2014-08-15
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT01204073 2013-07-02
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT01609179 2012-11-14
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
Infinity Pharmaceuticals, Inc.
Phase NA Completed